Johnson & Johnson (JNJ) is among the top 10 pharma stocks recommended by billionaires. With FDA approval for a subcutaneous induction regimen of Tremfya to treat ulcerative colitis, JNJ is making strides in immunology. The company is also expanding its oncology portfolio and reporting progress in Europe with nipocalimab for myasthenia gravis.

On the financial front, JNJ’s shares are up 20% year-to-date, driven by pharmaceutical growth and reduced legal risks. However, ongoing talc-related litigation remains a concern. Despite its potential, some believe that certain AI stocks offer greater upside potential and less downside risk.

Overall, Johnson & Johnson (JNJ) continues to strengthen its pharmaceuticals and immunology portfolio, with recent FDA approvals and promising trial data. While the company faces ongoing legal challenges, its financial performance has been strong. Investors are advised to consider the potential of JNJ alongside other AI stocks with growth potential.

Read more at Yahoo Finance: Johnson & Johnson (JNJ) Gains FDA Nod for Subcutaneous Tremfya in Ulcerative Colitis